Korearepublic Of to India: Paclitaxel Import Trade Route
India has recorded 1 verified shipments of Paclitaxel imported from Korearepublic Of, representing a combined trade value of $160.1K USD. This corridor is served by 1 active Korearepublic Of exporters, with an average shipment value of $160.1K USD. The leading Korearepublic Of supplier is SAMYANG HOLDINGS CORPORATION , which accounts for 100% of total import value with 1 shipments worth $160.1K USD. On the buying side, LUPIN LIMITED is the largest Indian importer with $160.1K USD in purchases. All data sourced from Indian Customs (DGFT) shipping bill of entry records. Values reported in FOB USD.
Route Intelligence Overview
The Korearepublic Of to India Paclitaxel corridor is one of India's established pharmaceutical import routes from Korearepublic Of, with 1 shipments documented worth a combined $160.1K USD. The route is dominated by SAMYANG HOLDINGS CORPORATION , which alone accounts for roughly 100% of all import value, reflecting the consolidated nature of Korearepublic Of's paclitaxel export sector.
Across 1 active Korearepublic Of suppliers, the average shipment value stands at $160.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (69%) and air (18%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.
Shipment activity peaks during July–September, with an average transit time of 21 days port-to-port. The route has recorded an annual growth rate of 30.7%, placing it at rank #1 among India's top paclitaxel import origins globally.
On the Indian buyer side, key Indian importers include LUPIN LIMITED . LUPIN LIMITED is the single largest Indian importer with 1 shipments valued at $160.1K USD.
Route Characteristics
- Average transit21 days
- Peak seasonQ3
- Primary modeMulti-modal
- Top port of entryBOMBAY AIR CARGO
Market Position
- Global rank#1
- Annual growth+30.7%
- Demand growth+27.5%
- Regulatory ease70/100
Top 10 Paclitaxel Exporters from Korearepublic Of to India
Showing top 10 of 1 Korearepublic Of suppliers exporting Paclitaxel to India, ranked by total trade value (USD)
| Rank | Supplier (Korearepublic Of Exporter) | Shipments | Total Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | SAMYANG HOLDINGS CORPORATION Avg $160.1K per shipment | 1 | $160.1K | 100.0% |
This table shows the top 10 of 1 Korearepublic Of companies exporting paclitaxel to India, ranked by total trade value. The listed exporters are: SAMYANG HOLDINGS CORPORATION . SAMYANG HOLDINGS CORPORATION is the dominant supplier with 1 shipments worth $160.1K USD, giving it a 100% market share.
Top 10 Indian Paclitaxel Importers from Korearepublic Of
Showing top 10 of 1 known Indian buyers receiving Paclitaxel shipments from Korearepublic Of, ranked by import value
On the receiving end of this trade route, the leading Indian importers of Korearepublic Of paclitaxel include LUPIN LIMITED . The largest importer is LUPIN LIMITED , accounting for $160.1K USD across 1 shipments — representing 100% of all paclitaxel imports from Korearepublic Of on this route.
| Rank | Indian Importer / Buyer | Shipments | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | LUPIN LIMITED | 1 | $160.1K | 100.0% |
Top 10 Paclitaxel Formulations Imported from Korearepublic Of
Showing top 10 of 1 product formulations shipped on the Korearepublic Of to India Paclitaxel route, ranked by trade value
India imports a wide range of paclitaxel formulations from Korearepublic Of, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — GENEXOL PM INJECTION 100 MG (PACLITAXEL 100MG/VIAL) 30 — accounts for $160.1K USD across 1 shipments. A total of 1 product variants have been identified in the shipment records.
| Rank | Product Formulation | Shipments | Trade Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | GENEXOL PM INJECTION 100 MG (PACLITAXEL 100MG/VIAL) 30 | 1 | $160.1K | 100.0% |
Shipping & Logistics Analysis
Freight mode split and port-of-origin breakdown
Freight Mode Distribution
Balanced freight mix — 69% sea for bulk, 18% air for urgent orders.
Top Indian Ports of Entry
BOMBAY AIR CARGO handles the highest volume with 1 shipments. Transit time averages 21 days by sea.
Market Dynamics
India's paclitaxel imports from Korearepublic Of are driven primarily by a handful of large-scale Korearepublic Of manufacturers. SAMYANG HOLDINGS CORPORATION with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — Indian buyers benefit from Korearepublic Of supplier diversity while the top tier handles the majority of volume.
The top 3 suppliers — SAMYANG HOLDINGS CORPORATION — together account for 100% of total trade value on this route. The average shipment value of $160.1K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.
On the buying side, LUPIN LIMITED is the largest importer with 1 shipments worth $160.1K USD — representing 100% of all paclitaxel imports from Korearepublic Of on this route.
Route Statistics
- Trade Volume
- $160.1K
- Avg. Shipment
- $160.1K
- Suppliers
- 1
- Buyers
- 1
- Transit (Sea)
- ~21 days
- Annual Growth
- +30.7%
Related Analysis
Other Paclitaxel Routes
Unlock the Full Korearepublic Of to India Paclitaxel Dataset
TransData Nexus provides verified shipment-level records, exporter contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 1 shipments on this route.
Frequently Asked Questions — Korearepublic Of to India Paclitaxel Trade
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which Korearepublic Of companies export Paclitaxel to India?
The leading Korearepublic Of exporters of Paclitaxel to India are SAMYANG HOLDINGS CORPORATION . SAMYANG HOLDINGS CORPORATION holds the largest market share at approximately 100% of total trade value on this route.
Q What is the total value of Paclitaxel imports from Korearepublic Of to India?
India imports Paclitaxel from Korearepublic Of worth approximately $160.1K USD across 1 recorded shipments. The average value per shipment is $160.1K USD.
Q Which Indian ports receive Paclitaxel from Korearepublic Of?
The most active Indian port of entry is BOMBAY AIR CARGO with 1 shipments. Korearepublic Of exporters primarily use a mix of sea and air freight for this route, with 69% of shipments going by sea and 18% by air.
Q How long does shipping take from Korearepublic Of to India for Paclitaxel?
The average transit time for Paclitaxel shipments from Korearepublic Of to India is approximately 21 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during July–September.
Q Is the Korearepublic Of to India Paclitaxel import route growing?
Yes — this trade corridor has seen an annual growth rate of approximately 30.7% with demand growth tracking at 27.5%. The route is ranked #1 among India's top Paclitaxel import origins globally.
Q How many Korearepublic Of suppliers are active on this Paclitaxel import route?
There are currently 1 active Korearepublic Of suppliers exporting Paclitaxel to India. The market is moderately concentrated with SAMYANG HOLDINGS CORPORATION accounting for 100% of total shipment value.
Q Who are the main Indian importers of Paclitaxel from Korearepublic Of?
The leading Indian importers of Paclitaxel from Korearepublic Of include LUPIN LIMITED . LUPIN LIMITED is the largest buyer with 1 shipments worth $160.1K USD.
Official References & Regulatory Resources
- India Trade Statistics (DGFT)
- Invest India — Pharma Sector
- WCO HS Nomenclature
- Ministry of Commerce — Pharma Exports
- Pharmexcil
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Route Identification: India to Korearepublic Of export trade corridor identified from Indian Customs (DGFT) records for Paclitaxel.
- 2.Supplier/Buyer Matching: 1 Indian exporters and 1 importers in Korearepublic Of matched using name normalization.
- 3.Value Aggregation: Total export value aggregated from 1 verified shipping bill records. Values are FOB in USD.
- 4.Market Share Analysis: Each supplier and buyer contribution calculated as a percentage of total route value. Statistical normalization applied to ensure accurate representation across varying shipment sizes.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 Indian exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists